MEA Autoimmune Monoclonal Antibodies Market

MEA Autoimmune Monoclonal Antibodies Market Size (2024 to 2029)

The size of the Autoimmune Monoclonal Antibodies Market in the Middle East and Africa is expected to reach USD 1873.33 million by 2029 from USD 1349.47 million in 2024, growing at a CAGR of 6.78% during the forecast period.

The rising prevalence of cancer and other chronic diseases, rising regulatory approvals and therapy launches, and growing research collaborations for the development of a robust drug pipeline are the major factors driving the growth of the Middle East and Africa autoimmune monoclonal antibodies market over the forecast period. The participants of the market are investing heavily in research and development to create treatments with fewer negative effects for patients. These strategies are the players' last resort in order to compete in the market for MEA anti-CD20 monoclonal antibodies.

However, the majority of these medications come with adverse effects, which leads to limited patient adherence. Due to these adverse effects, as well as numerous research and advances in the field of targeted therapies, such as anti-CD20 mABs, the number of targeted therapies, such as anti-CD20 mABs, has expanded over time.

This research report on the MEA Autoimmune Monoclonal Antibodies Market has been segmented and sub-segmented into the following categories

By Source

• Murine
• Chimeric
• Humanized
• Human

By Application

• Systemic Lupus Erythematosus

• Rheumatoid Arthritis
• Multiple Sclerosis
• Transplant Rejection/Graft Versus Host Disease

By End-User

• Hospitals/Clinics
• Research Institutes
• Diagnostic Laboratories

By Country

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

During the forecast period, the MEA market is expected to register a healthy growth rate. Countries such as the United Arab Emirates and Kuwait have proven to be highly beneficial as target therapies in the treatment of cancer indications. These medications specifically target the CD20 antigen on cancer cells, which is not possible with standard treatments. The regional expansion of the MEA anti-CD20 monoclonal antibodies (mABs) market is projected to be boosted by increasing inventions in this field and several affirmative clinical trials.

KEY MARKET PLAYERS

Companies such as GlaxoSmithKline plc (U.K.), AstraZeneca plc (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb (U.S.), Johnson & Johnson (U.S.), Innovent Biologics, Inc. (China), Takeda Pharmaceutical Company Ltd. (Japan), Amgen Inc. (U.S.), Biogen Inc. (U.S.), and UCB Company (Belgium) are playing a leading role in the MEA Autoimmune Monoclonal Antibodies Market.